You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,240,832

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,240,832
Title: Heteropolymeric protein production methods
Abstract:Cultured mammalian cells transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.
Inventor(s): Kelton; Christie A. (Hopkinton, MA), Nugent; Noreen P. (Framingham, MA), Chappel; Scott C. (Boston, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:07/780,556
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,240,832
Patent Claims:1. A method for the production of thyroid stimulating hormone comprising the steps of:

a) providing a first vector comprising a promoter, a DNA fragment encoding for the alpha subunit of said thyroid stimulating hormone and comprising at least one intron, and a terminating sequence, and a second vector comprising a promoter, a DNA fragment TSHB 1.2 or TSHB 2.0 encoding for the beta subunit of said thyroid stimulating hormone consisting essentially of coding exons II and III separated by an endogenous intervening sequence, and one intron about 300 base pairs in length positioned upstream of and adjacent to exon II, and a terminating sequence;

b) transforming host cells with said vectors; and

c) culturing said transformed cells under conditions whereby said thyroid stimulating hormone is produced.

2. The method of claim 1 wherein said DNA fragment encoding said .alpha. subunit further comprises a plurality of introns, 3' and 5' flanking regions, endogenous 5' untranslated sequence and polyadenylation signal.

3. The method of claim 1 wherein said selected dimeric protein is human thyroid stimulating hormone.

4. The method of claim 1 wherein said selected dimeric protein is non-human thyroid stimulating hormone.

5. The method of claim 3 wherein the DNA fragment for the beta subunit of human thyroid stimulating hormone is a 1.2 kb DNA fragment containing the two coding exons separated by an endogenous intervening sequence, but without the endogenous polyadenylation signal or additional 3' flanking sequence.

6. The method of claim 3 wherein the DNA fragment for the beta subunit of human thyroid stimulating hormone is a 2.0 kb DNA fragment containing the two coding exons separated by an endogenous intervening sequence, and including the endogenous polyadenylation signal and 0.8 kb of additional 3' flanking sequence.

Details for Patent 5,240,832

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Genzyme Corporation (Cambridge, MA) 2010-08-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Genzyme Corporation (Cambridge, MA) 2010-08-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Genzyme Corporation (Cambridge, MA) 2010-08-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
AstraZeneca
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.